A multicenter study on the safety of tapentadol

A retrospective multicenter study to determine the clinical characteristics of tapentadol - A retrospective multicenter study on tapentadol

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044282

Enrollment

600

Registered

2021-05-25

Start date

2021-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with carcinoma who started taking tapentadol from August 18th, 2014 to October 31th, 2019.

Exclusion criteria

Exclusion criteria: 1) Patients for whom the start date of tapentadol is unknown 2) Patients deemed inappropriate for inclusion at the discretion of the principal investigator or sub-investigator

Design outcomes

Primary

Measure	Time frame
Ratio of discontinuation of medication due to adverse events	—

Countries

Japan

Contacts

Public ContactKessoku Takaomi

Yokohama City University Hospital Department of Palliative Medicine

takaomik@yokohama-cu.ac.jp0457872800

Outcome results